SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 13, 2007
Blonder Tongue Laboratories, Inc.
(Exact Name of registrant as specified in its charter)
Delaware 1-14120 52-1611421
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification No.)
One Jake Brown Road, Old Bridge, New Jersey 08857
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (732) 679-4000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. REGULATION FD DISCLOSURE.
On February 13, 2007, Blonder Tongue Laboratories, Inc. (the "Company") issued a
press release announcing its Board of Directors authorized a new stock
repurchase program. The press release is attached hereto as Exhibit 99.1 and is
incorporated into this Item 7.01 by reference.
ITEM 8.01. OTHER EVENTS.
On February 13, 2007, the Company announced that its Board of Directors has
authorized a new stock repurchase program to acquire up to 100,000 shares of its
outstanding common stock. This authorization supplements the existing stock
repurchase plan adopted in July 2002, under which the Company may still expend
approximately $100,000 to acquire additional shares of its common stock. The
Company intends to resume making purchases under the July 2002 plan up to its
limits, and thereafter to make purchases under the new 100,000 share program.
Purchases will be funded from available working capital and the repurchased
shares may be retired or may be held in treasury or used for ongoing stock
issuance such as for employee stock plans.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
Exhibit Number Description
Exhibit 99.1 Press Release of Blonder Tongue Laboratories, Inc.
issued February 13, 2007
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BLONDER TONGUE LABORATORIES, INC.
By:/s/ Eric Skolnik
Eric Skolnik
Senior Vice President
and Chief Financial Officer
Date: February 13, 2007
3
EXHIBIT INDEX
Exhibit Number Description
Exhibit 99.1 Press Release of Blonder Tongue Laboratories, Inc.
issued February 13, 2007
4
